Abstract
Accumulation of somatic mutations and genomic instability are hallmarks of both aging and cancer. Epigenetic alterations occur across cell types and tissues with advancing age. DNA methylation-based estimates of biologic age can predict important age-related outcomes, including risk of frailty and mortality, and most recently have been shown to be associated with risk of developing cancer. In this mini-review, we examine pathways known to exhibit altered methylation in aging tissues, pre-malignant lesions, and tumors and review methodologies of epigenetic clocks that reliably predict cancer risk, including those derived from methylation studies of peripheral blood, as well as those methylation levels from within the tissues at high risk of cancer.
Introduction
Cancer incidence increases exponentially with advancing age, beginning at the midpoint of the lifespan in most mammalian species (Campisi and Yaswen, 20092009). Somatic mutations accumulate within cells with chronic cell cycling (Moskalev et al., 2013), leading to genomic instability, a hallmark of both aging and cancer (Hanahan and Weinberg, 2011; López-OtÃn et al., 2013). Over the past decade, epigenetic alterations that occur with advancing age across cell types and tissues have been identified (Teschendorff et al., 2010; Horvath, 2013), and methylation markers at select sites have been shown to reliably predict chronologic age (Teschendorff et al., 2010; Bocklandt et al., 2011; Hannum et al., 2013; Horvath, 2013). Epigenetic clocks have been further shown to predict age-related diseases and outcomes, including frailty and mortality, suggesting that they are reliable markers of biologic aging (Chen et al., 2016; Levine et al., 2018; Lu et al., 2019a). Importantly, methylation age has recently also been associated with cancer risk (Levine et al., 2015; Lu et al., 2019a; Yu et al., 2020). In this article, we will review studies of global methylation alterations that occur with advancing age and cancer risk, compare the development and features of first- and second-generation epigenetic clocks, as well as the epigenetic pacemaker clock and other methods, and illustrate their ability to predict risk of incident cancer.
Pathways With Aberrant Methylation in Malignant Tissues
DNA methylation is thought to play an important role in the etiology of complex traits, including cancer (Esteller, 2008; Petronis, 2010). The importance of DNA methylation in carcinogenesis was recognized with the discovery of numerous hypermethylated promoters of tumor suppressor genes in tumor samples, as well as findings confirming the role of DNA methylation in facilitating DNA damage, e.g., in the silencing of mismatch repair genes (Jones and Laird, 1999). Hundreds of genes, including key tumor suppressor genes, are hypermethylated at promoter CpG islands, and are either transcriptionally silenced or blocked from normal induction, in nearly every patient’s cancer compared with normal cell counterparts (Vaissière et al., 2009; Baylin and Jones, 2016; Xie et al., 2018). The similarity in epigenetic alterations that occur during tumorigenesis and senescence raises the question of whether programmatic changes that occur during senescence play a role in carcinogenesis. Though the promoter hypermethylation events in malignant transformation appear to arise independently of cellular senescence (Xie et al., 2018), further exploration is needed to identify a relationship between cancer risk and epigenetic events occurring in development and aging.
Age-Dependent Hypermethylation of Polycomb Group Target Proteins
Polycomb group proteins repress genes required for stem cell differentiation, and targets of polycomb group proteins (PCGTs) are repressed in human embryonic and adult stem cells through reversible chromatin modifications (Lee et al., 2006). PCGTs are 12-fold more likely to be methylated in cancer tissues than non-PCGTs, suggesting a mechanism of carcinogenesis where cells are locked in an un-differentiated state of self-renewal and predisposed to malignant transformation. In an analysis of whole blood samples from 261 postmenopausal women, Teschendorff demonstrated that PCGT CpGs are hypermethylated with advancing age, and this methylation signature was validated in seven independent data sets encompassing 900 samples, from multiple cell types and tissues including blood, ovarian cancer, cervix, and marrow mesenchymal stem and stromal cells (Teschendorff et al., 2010).
Variability in Age-Related Methylation Patterns in Premalignant Lesions
Methylation markers drift differentially with age between normal and premalignant tissues. In pre-malignant dysplastic tissues, age-PCGT CpGs were more highly methylated than in normal samples, suggesting that age may contribute to carcinogenesis by irreversibly silencing genes that are suppressed in stem cells (Teschendorff et al., 2010). Importantly, in dysplastic tissues, differential variability in methylation identifies cancer risk markers more reliably than differences in mean methylation (Teschendorff and Widschwendter, 2012). Differentially variable features identified in precursor non-invasive lesions exhibit significantly increased enrichment for developmental genes compared with differentially methylated sites (Teschendorff and Widschwendter, 2012). In studies of normal and pre-malignant esophageal tissues, differential methylomic drift occurs in Barrett’s esophagus (BE) relative to normal squamous tissue (Curtius et al., 2016). Using a Bayesian model incorporating longitudinal methylomic drift rates, patient age, and methylation data from BE and normal squamous tissue, Curtius et al. have developed a molecular clock to reliably estimate patient-specific BE onset times, providing information about how long an individual has lived with the precursor lesion (Curtius et al., 2016).
DNA Methylation-Based Estimates of Age
Table 1 summarizes 16 epigenetic clocks that have been developed over the past decade. These clocks reliably estimate chronologic age based on methylation levels at select CpGs (Di Lena et al., 2021). In an early work analyzing methylation patterns in saliva associated with advancing age, lasso penalized regression was used to screen for the top predictors of age, and a leave-one-out regression analysis was used to form an accurate epigenetic predictor of age (Bocklandt et al., 2011). Subsequently, Horvath developed a multi-tissue epigenetic clock across 51 healthy tissues and cell types, that reliably estimated methylation age across cell types and tissues (Horvath, 2013). This epigenetic clock was found to be close to zero for embryonic and induced pluripotent stem cells, applied across species to chimpanzees (Horvath, 2013), and importantly was later found to be accelerated in disease states (Horvath et al., 2014; Rickabaugh et al., 2015) and predictive of frailty and mortality (Chen et al., 2016). This clock utilizes elastic net regression on a transformed continuous, monotonically increasing function of age to select a set of CpGs whose weighted average reliably predict age across a wide spectrum of tissues and cell types. Elastic net regression linearly combines the l1 (lasso) and l2 (ridge) penalty terms. While the lasso tends to select only one variable from a group of highly correlated variables, the quadratic expression elevates the loss function toward being convex, allowing a larger number of variables to be included when there is a higher correlation of variables and higher grouping effect. To avoid low efficiency in predictability and high bias from subjecting coefficients to two types of shrinkages, coefficients are rescaled by multiplying them by (1 + l2). The Hannum clock similarly uses elastic net regression to estimate chronologic age from methylation levels at 71 CpGs in peripheral blood (Hannum et al., 2013). Blood-based epigenetic age measures Intrinsic and Extrinsic epigenetic age incorporate information on cell composition (imputed from methylation data at additional sites) to estimate age. While Intrinsic epigenetic age is independent of changes in cell distribution that occur with advancing age, Extrinsic epigenetic age is positively and negatively correlated with estimated proportions of naïve and senescent cytotoxic T lymphocytes. More recently, second generation clocks have been developed, including Phenotypic age (Levine et al., 2018) and Grim age (Lu et al., 2019a) which are both more closely associated with lifespan, and utilize a two-step process to estimate biologic age. In the development of the Phenotypic age clock, first 1) Cox penalized regression is used to identify a set of biomarkers that best predict aging-related mortality, and next 2) a mortality score based on the regression coefficients from step 1 is converted into units of years and the resultant phenotypic age estimate is regressed on DNA methylation using an elastic net regression analysis. Grim age clock also involves a two-step process in which 1) methylation data is used to estimate smoking pack-years and levels of plasma proteins known to be associated with morbidity or mortality, and 2) time-to-death is regressed on these DNA methylation-based surrogate biomarkers, resulting in a mortality risk estimate that is transformed into units of years. The Skin and Blood clock is a robust estimator of methylation age in fibroblasts, keratinocytes, buccal cells, endothelial cells, lymphoblastoid cells, skin, blood, and saliva, and was developed when it was found that other clocks performed poorly in human fibroblasts and other skin cells (Horvath et al., 2018). A DNA methylation-based estimate of telomere length, DNAmTL, is a measure of cell replicative history, and outperforms measured leukocyte telomere length in predicting time to death and age-related pathologies (Lu et al., 2019b). Stubbs et al. developed an accurate multi-tissue age estimator in mice, with CpGs from pathways involved in morphogenesis and development (Stubbs et al., 2017). Additional clocks have been developed to more accurately predict age in human cortical tissue (Shireby et al., 2020), skeletal muscle (Voisin et al., 2020), and pediatric buccal epithelial (McEwen et al., 2020) tissues. Finally, epigenetic clocks have been developed to predict gestation age using methylation levels of cells from umbilical cord and placental tissues (Bohlin et al., 2016; Knight et al., 2016; Mayne et al., 2017; Lee et al., 2019).
TABLE 1
| Clock | Methods | # CpGs | Pathways | Special Features | Ref |
|---|---|---|---|---|---|
| Pan-tissue | Elastic net | 353 | Survival, apoptosis, self renewal | Reliable across cell types and tissues | 5 |
| Hannum | Elastic net | 71 | Cell cycle regulation, DNA repair, iron homeostasis | Widely used in epidemiologic studies | 8 |
| Phenotypic | Cox penalized regression + elastic net | 513 | JAK-STAT cascade, tumor necrosis, NFkB, lipopolysaccharide | Strong predictor of healthspan and lifespan | 11 |
| Grim | Cox penalized regression + elastic net | 1,030 | MHC II, cytokine signaling, protein sumoylation | Strongest predictor of mortality | 10 |
| EpiTOC | Informed selection | 385 | Stem cell renewal and differentiation | Estimated rate of stem cell division | 37 |
| Skin and Blood | Elastic net | 391 | Survival, apoptosis, selfrenewal, cell cycle regulation, DNA repair | Most accurate predictor of age in skin and fibroblasts | 25 |
| Epigenetic pacemaker | Conditional expectation maximization | varies | variable | Accounts for nonlinearities in aging rates | 27 |
| DNAmTL | Elastic net | 140 | Cadherin, cell signaling | Marker of cell replicative history | 26 |
| Mouse clock | Elastic net | 329 | Development, morphogenesis | Multi-tissue predictor in mice | 28 |
| Human cortex clock | Elastic net | 347 | None reported | Accurate in human cerebral cortex | 29 |
| Skeletal muscle clock | Elastic net | 200 | None reported | Accurate in human skeletal muscle | 30 |
| PedBE clock | Elastic net | 94 | None reported | Accurate in buccal cells of children | 31 |
| Gestational age clocks | Elastic net, lasso | 148, 62, 58, 5,474 | Cell aging and senescence | Umbilical cord blood and placenta at birth; predictive of gestational age | 32–35 |
Features of epigenetic clocks.
Despite high accuracy, epigenetic clocks do not permit characterization of the non-linear epigenetic aging patterns that occur across the entire lifespan. Recently, a new method was developed to model epigenetic changes with age while accounting for the nonlinearities of this relationship that occur with advancing age (Snir et al., 2019). This integrated framework, based on evolutionary models, addresses the acceleration and deceleration of epigenetic changes that occur over time, and has been applied to methylation data from broad age ranges and multiple tissue types. The Epigenetic Pacemaker (EPM) employs a fast conditional expectation maximization algorithm to model epigenetic states associated with a phenotype of interest, such as aging and type 2 diabetes mellitus. In this algorithm, each methylation site is assigned an independent rate of change and starting methylation value, while each individual is assigned an epigenetic state. Given methylation sites and individuals, a single methylation site can be described as:Where is the observed methylation value, is the initial methylation value, is the rate of change, is the epigenetic state, and is a normally distributed error term. The goal of the EPM is to find the optimal values of the initial methylation value, rate of change, and epigenetic state to minimize the error between the predicted and observed methylation values across a system of methylation sites. The epigenetic state is then updated through each iteration of the EPM to minimize the error across the observed epigenetic landscape. Because the epigenetic state is updated while fitting the EPM, the assumption of linearity between the methylation values and the phenotypic trait of interest is relaxed. In addition to examining age as an outcome of interest, these models can be employed to study additional phenotypes of interest, including risk of cancer.
Epigenetic Clocks Predicting Risk of Cancer
Older tissues are at greater risk of malignant transformation because of acquired mutations that occur in the setting of prolonged epithelial proliferation. Several recent studies have demonstrated that accelerated aging in peripheral blood predicts subsequent development of cancer (Levine et al., 2015; Kresovich et al., 2019a; Zheng et al., 2016; Perna et al., 2016; Durso et al., 2017; Kresovich et al., 2019b). Table 2 summarizes epigenetic clocks that have demonstrated association with cancer risk. Pan-tissue clock acceleration in peripheral blood is associated with later development of lung cancer (Levine et al., 2015), breast cancer (Durso et al., 2017), and male colon cancer (Durso et al., 2017). Grim age, a strong predictor of mortality, is associated with time to any cancer (Lu et al., 2019a). Intrinsic epigenetic age acceleration in peripheral blood is associated with risk of post-menopausal breast cancer, with epigenetic acceleration detected up to 10 years prior to cancer diagnosis (Ambatipudi et al., 2017). In a large study examining methylation in 2,764 cancer free women in the Sister Study, 1,566 of whom subsequently developed breast cancer after an average of 6 years, acceleration of Pan-tissue age, Hannum age, and Phenotypic age each predicted risk of subsequent breast cancer (Kresovich et al., 2019b). In this study, Grim age was associated with invasive breast cancer in post-menopausal women (Kresovich et al., 2019a). Using data from seven nested case-control studies of peripheral blood DNA methylation and colorectal, gastric, kidney, lung, prostate, and urothelial cancer, and B cell lymphoma from the Melbourne Collaborative Cohort Study, epigenetic aging was associated with both risk of cancer and increased risk of death after cancer diagnosis (Dugué et al., 2018). A five-year increase in age acceleration was associated with a 4–9% increase in risk of cancer, and a 2–5% increased risk of death following cancer diagnosis (Dugué et al., 2018).
TABLE 2
| Epigenetic clock | Tumor type | Ref |
|---|---|---|
| Grim age (blood) | Time to cancer (all), invasive breast cancer in post-menopausal women | 10, 28 |
| Intrinsic age (blood) | Breast cancer risk | 33 |
| Pan-tissue age (blood) | Lung, breast cancer risk, other cancers | 12, 32, 34 |
| Hannum age (blood) | Breast cancer risk | 32 |
| Phenotypic age (blood) | Breast cancer risk | 32 |
| Pan-tissue (colon cancers) | Cancer subtype, prognosis | 35 |
| Pan-tissue (breast tumors) | More aggressive breast cancers in younger women | 36 |
| EpiTOC (precancerous lesions and cancer) | Accelerated in precancerous lesions and cancer | 37 |
| MiAge calculator (13 cancer types and adjacent normal tissues) | Accelerated mitotic age in tumor tissues is associated with worse survival | 47 |
Epigenetic clocks predictive of cancer risk.
In addition to the associations found between cancer risk and epigenetic aging in peripheral blood, several studies have examined age-related epigenetic changes in tissues that subsequently develop cancer. Epigenetic aging is associated with cancer risk (in at-risk tissues) and prognosis (in cancerous tissues). For example, Pan-tissue age acceleration in colon cancer samples has been linked with colon cancer molecular subtypes and improved prognosis prediction because it is linked with overall survival (Zheng et al., 2019). In breast tumor samples, methylation studies within the breast of very young women with more aggressive breast cancer exhibit accelerated DNA methylation age compared with breast cancer in older counterparts, suggesting a role of accelerated epigenetic aging in breast cancer risk (Oltra et al., 2019). In addition, methylation-based markers of cell replication have been associated with cancer risk, including the epigenetic mitotic clock (EpiTOC) which approximates the rate of stem cell division in normal tissues by focusing on promoter CpG sites that localize to PCGT genes, and has been shown to be accelerated in precancerous lesions and cancer (Yang et al., 2016). Furthermore, Youn et al. demonstrated that quantitative estimates of mitotic age (total number of cell divisions) of a tissue, derived using the stochastic replication errors accumulated during cell divisions predict shorter disease associated survival in thirteen cancer types studied (Youn and Wang, 2018). In healthy breast tissue, methylation of tumor suppressor genes APC (Lewis et al., 2005; Euhus et al., 2008) and RASSF1 (Lewis et al., 2005) is associated with breast cancer risk as measured by the Gail model risk score. In a recent study comparing disease-free breast tissue cores from women at high versus average risk for breast cancer using the Tyrer-Cuzick model, 1698 DNA methylation aberrations were identified in high-risk breast tissues, from pathways involving cell adhesion, ErbB, and protein kinase A signaling (Marino et al., 2021). A global study of age-related DNA methylation changes in healthy breast demonstrated that increased methylation primarily occurs at enhancer regions of binding sites for chromatin remodeling genes (Johnson et al., 2017). Epigenetic age of healthy breast is elevated above chronologic age and appears older with other tissues in the body (Horvath, 2013; Sehl et al., 2017), including matched peripheral blood samples from healthy breast tissue donors (Sehl et al., 2017). Estrogen stimulation and chronic cell cycling are thought to drive accelerated aging in breast tissue (Pike et al., 1983; Pike et al., 1993). Risk factors for breast cancer that relate to lifetime estrogen exposure, including earlier menarche and elevated body mass index, are associated with accelerated Grim age in healthy breast tissue (Sehl et al., 2021). Likewise Pan-tissue age, Hannum age, and Phenotypic age in peripheral blood are associated with risk factors for breast cancer, including BMI and alcohol use (Chen et al., 2019). Furthermore, in peripheral blood, an epigenome wide analysis of estimated lifetime estrogen exposure (ELEE) in 216 women in the EPIC-Italy study identified a methylation index of ELEE based on 694 CpGs, and developed a methylation index based on 31 of these most varying CpGs that predicted subsequent breast cancer risk in 440 women with incident breast cancer and 440 controls from the Generations Study (Johansson et al., 2019). An increase of DNA methylationbased ELEE of 1Â year was associated with a 5% increase in breast cancer risk (Johansson et al., 2019).
DNA methylation studies comparing normal adjacent breast tissue from women with breast cancer and healthy tissues from cancer-free women revealed epigenetic field effects, with aberrant methylation in specific pathways related to stem cell differentiation, including WNT signaling, known to be epigenetically deregulated in cancer (Teschendorff et al., 2016). Furthermore, epigenetic age in normal adjacent breast tissue from luminal breast cancer patients is increased compared with healthy breast tissue from donors with no history of breast cancer (Hofstatter et al., 2018). In a recent study of 107 breast tumor samples compared with 45 paired adjacent-normal breast tissue samples and 459 normal breast samples, DNA methylation age was estimated using 286 CpGs out of over two million candidate CpGs. Breast tumor samples exhibited age acceleration, appeared 12 and 13Â years older than adjacent normal and normal breast tissue with identified pathways involving cellular development and morphology, epidermal growth factor and estrogen receptor signaling (Castle et al., 2020).
Finally, a recent study of epigenetic age-related methylation changes in healthy mammary epithelial tissues demonstrated accelerated epigenetic aging in 12 women with germline mutations in cancer susceptibility genes (Miyano et al., 2021). This study used a breast-specific molecular clock based on methylation of ELF5, a marker critical for mammary development. This finding suggests a link between inherited alterations in DNA repair capacity and accelerated epigenetic aging in tissues at highest risk of developing malignancy.
Conclusion and Future Directions
DNA methylation-based estimates of biologic age are associated with both cancer risk factors and risk of incident cancer, suggesting a potential mechanistic link between genomic instability, epigenetic age acceleration, and carcinogenesis. Further work is needed to investigate alterations in transcriptomic and proteomic pathways that accompany epigenetic age acceleration prior to the development of cancer. Identification of these changes could lead to targets for chemoprevention in individuals at high risk for cancer. In addition, future studies should identify nonlinear trends in epigenetic age that are associated with cancer risk and modeling epigenetic states that are associated with risk of cancer. Integrative analyses of methylation age along with genomic, transcriptomic, and proteomic data within an individual prior to the development of cancer may ultimately be used to develop predictive tools that could be used to guide risk reduction strategies.
Statements
Author contributions
All authors contributed to the conceptualization, review of the literature, and writing of the manuscript. All authors have approved the completed version of the manuscript and are accountable for all aspects of the work.
Funding
This study was funded by a Susan G. Komen Career Catalyst Award for Basic and Translational Science CCR16380478. PAG was supported by the Breast Cancer Research Foundation (BCRF). PAG severs on the scientific advisory board for the BCRF.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AmbatipudiS.HorvathS.PerrierF.CueninC.Hernandez-VargasH.Le Calvez-KelmF.et al (2017). DNA Methylome Analysis Identifies Accelerated Epigenetic Ageing Associated with Postmenopausal Breast Cancer Susceptibility. Eur. J. Cancer75, 299–307. 10.1016/j.ejca.2017.01.014
2
BaylinS. B.JonesP. A. (2016). Epigenetic Determinants of Cancer. Cold Spring Harb Perspect. Biol.8 (9). 10.1101/cshperspect.a019505
3
BocklandtS.LinW.SehlM. E.SánchezF. J.SinsheimerJ. S.HorvathS.et al (2011). Epigenetic Predictor of Age. PLoS One6 (6), e14821. 10.1371/journal.pone.0014821
4
BohlinJ.HÃ¥bergS. E.MagnusP.ReeseS. E.GjessingH. K.MagnusM. C.et al (2016). Prediction of Gestational Age Based on Genome-wide Differentially Methylated Regions. Genome Biol.17 (1), 207. 10.1186/s13059-016-1063-4
5
CampisiJ.YaswenP. (20092009). Aging and Cancer Cell Biology, 2009. Aging Cell8 (3), 221–225. 10.1111/j.1474-9726.2009.00475.x
6
CastleJ. R.LinN.LiuJ.StornioloA. M. V.ShendreA.HouL.et al (2020). Estimating Breast Tissue-specific DNA Methylation Age Using Next-Generation Sequencing Data. Clin. Epigenetics12 (1), 45. 10.1186/s13148-020-00834-4
7
ChenB. H.MarioniR. E.ColicinoE.PetersM. J.Ward-CavinessC. K.TsaiP. C.et al (2016). DNA Methylation-Based Measures of Biological Age: Meta-Analysis Predicting Time to Death. Aging (Albany NY)8 (9), 1844–1865. 10.18632/aging.101020
8
ChenM.WongE. M.NguyenT. L.DiteG. S.StoneJ.DuguéP. A.et al (2019). DNA Methylation-Based Biological Age, Genome-wide Average DNA Methylation, and Conventional Breast Cancer Risk Factors. Sci. Rep.9 (1), 15055. 10.1038/s41598-019-51475-4
9
CurtiusK.WongC. J.HazeltonW. D.KazA. M.ChakA.WillisJ. E.et al (2016). A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus. Plos Comput. Biol.12 (5), e1004919. 10.1371/journal.pcbi.1004919
10
Di LenaP.SalaC.NardiniC. (2021). Estimage: a Webserver Hub for the Computation of Methylation Age. Nucleic Acids Res.49 (W1), W199–W206. 10.1093/nar/gkab426
11
DuguéP. A.BassettJ. K.JooJ. E.JungC. H.Ming WongE.Moreno-BetancurM.et al (2018). DNA Methylation-Based Biological Aging and Cancer Risk and Survival: Pooled Analysis of Seven Prospective Studies. Int. J. Cancer142 (8), 1611–1619. 10.1002/ijc.31189
12
DursoD. F.BacaliniM. G.SalaC.PirazziniC.MarascoE.BonaféM.et al (2017). Acceleration of Leukocytes' Epigenetic Age as an Early Tumor and Sex-specific Marker of Breast and Colorectal Cancer. Oncotarget8 (14), 23237–23245. 10.18632/oncotarget.15573
13
EstellerM. (2008). Epigenetics in Cancer. N. Engl. J. Med.358 (11), 1148–1159. 10.1056/NEJMra072067
14
EuhusD. M.BuD.MilchgrubS.XieX. J.BianA.LeitchA. M.et al (2008). DNA Methylation in Benign Breast Epithelium in Relation to Age and Breast Cancer Risk. Cancer Epidemiol. Biomarkers Prev.17 (5), 1051–1059. 10.1158/1055-9965.EPI-07-2582
15
HanahanD.WeinbergR. A. (2011). Hallmarks of Cancer: the Next Generation. Cell144 (5), 646–674. 10.1016/j.cell.2011.02.013
16
HannumG.GuinneyJ.ZhaoL.ZhangL.HughesG.SaddaS.et al (2013). Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. Mol. Cel49 (2), 359–367. 10.1016/j.molcel.2012.10.016
17
HofstatterE. W.HorvathS.DalelaD.GuptaP.ChagparA. B.WaliV. B.et al (2018). Increased Epigenetic Age in normal Breast Tissue from Luminal Breast Cancer Patients. Clin. Epigenetics10 (1), 112. 10.1186/s13148-018-0534-8
18
HorvathS. (2013). DNA Methylation Age of Human Tissues and Cell Types. Genome Biol.14 (10), R115. 10.1186/gb-2013-14-10-r115
19
HorvathS.ErhartW.BroschM.AmmerpohlO.von SchönfelsW.AhrensM.et al (2014). Obesity Accelerates Epigenetic Aging of Human Liver. Proc. Natl. Acad. Sci. U S A.111 (43), 15538–15543. 10.1073/pnas.1412759111
20
HorvathS.OshimaJ.MartinG. M.LuA. T.QuachA.CohenH.et al (2018). Epigenetic Clock for Skin and Blood Cells Applied to Hutchinson Gilford Progeria Syndrome and Ex Vivo Studies. Aging (Albany NY)10 (7), 1758–1775. 10.18632/aging.101508
21
JohanssonA.PalliD.MasalaG.GrioniS.AgnoliC.TuminoR.et al (2019). Epigenome-wide Association Study for Lifetime Estrogen Exposure Identifies an Epigenetic Signature Associated with Breast Cancer Risk. Clin. Epigenetics11 (1), 66. 10.1186/s13148-019-0664-7
22
JohnsonK. C.HousemanE. A.KingJ. E.ChristensenB. C. (2017). Normal Breast Tissue DNA Methylation Differences at Regulatory Elements Are Associated with the Cancer Risk Factor Age. Breast Cancer Res.19 (1), 81. 10.1186/s13058-017-0873-y
23
JonesP. A.LairdP. W. (1999). Cancer Epigenetics Comes of Age. Nat. Genet.21 (2), 163–167. 10.1038/5947
24
KnightA. K.CraigJ. M.ThedaC.Baekvad-HansenM.Bybjerg-GrauholmJ.HansenC. S.et al (2016). An Epigenetic Clock for Gestational Age at Birth Based on Blood Methylation Data. Genome Biol.17 (1), 206. 10.1186/s13059-016-1068-z
25
KresovichJ. K.XuZ.O'BrienK. M.WeinbergC. R.SandlerD. P.TaylorJ. A. (2019). Epigenetic Mortality Predictors and Incidence of Breast Cancer. Aging (Albany NY)11 (24), 11975–11987. 10.18632/aging.102523
26
KresovichJ. K.XuZ.O'BrienK. M.WeinbergC. R.SandlerD. P.TaylorJ. A. (2019). Methylation-Based Biological Age and Breast Cancer Risk. J. Natl. Cancer Inst.111 (10), 1051–1058. 10.1093/jnci/djz020
27
LeeT. I.JennerR. G.BoyerL. A.GuentherM. G.LevineS. S.KumarR. M.et al (2006). Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells. Cell125 (2), 301–313. 10.1016/j.cell.2006.02.043
28
LeeY.ChoufaniS.WeksbergR.WilsonS. L.YuanV.BurtA.et al (2019). Placental Epigenetic Clocks: Estimating Gestational Age Using Placental DNA Methylation Levels. Aging (Albany NY)11 (12), 4238–4253. 10.18632/aging.102049
29
LevineM. E.HosgoodH. D.ChenB.AbsherD.AssimesT.HorvathS. (2015). DNA Methylation Age of Blood Predicts Future Onset of Lung Cancer in the Women's Health Initiative. Aging (Albany NY)7 (9), 690–700. 10.18632/aging.100809
30
LevineM. E.LuA. T.QuachA.ChenB. H.AssimesT. L.BandinelliS.et al (2018). An Epigenetic Biomarker of Aging for Lifespan and Healthspan. Aging (Albany NY)10 (4), 573–591. 10.18632/aging.101414
31
LewisC. M.ClerL. R.BuD. W.Zöchbauer-MüllerS.MilchgrubS.NaftalisE. Z.et al (2005). Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk. Clin. Cancer Res.11 (1), 166–172.
32
López-OtÃnC.BlascoM. A.PartridgeL.SerranoM.KroemerG. (2013). The Hallmarks of Aging. Cell153 (6), 1194–1217. 10.1016/j.cell.2013.05.039
33
LuA. T.QuachA.WilsonJ. G.ReinerA. P.AvivA.RajK.et al (2019). DNA Methylation GrimAge Strongly Predicts Lifespan and Healthspan. Aging (Albany NY)11 (2), 303–327. 10.18632/aging.101684
34
LuA. T.SeebothA.TsaiP. C.SunD.QuachA.ReinerA. P.et al (2019). DNA Methylation-Based Estimator of Telomere Length. Aging (Albany NY)11 (16), 5895–5923. 10.18632/aging.102173
35
MarinoN.GermanR.PodichetiR.RushD. B.RockeyP.HuangJ.et al (2021). Aberrant Epigenetic and Transcriptional Events Associated with Breast Cancer Risk. bioRxiv1, 1. 10.1101/2021.09.14.460320
36
MayneB. T.LeemaqzS. Y.SmithA. K.BreenJ.RobertsC. T.Bianco-MiottoT. (2017). Accelerated Placental Aging in Early Onset Preeclampsia Pregnancies Identified by DNA Methylation. Epigenomics9 (3), 279–289. 10.2217/epi-2016-0103
37
McEwenL. M.O'DonnellK. J.McGillM. G.EdgarR. D.JonesM. J.MacIsaacJ. L.et al (2020). The PedBE Clock Accurately Estimates DNA Methylation Age in Pediatric Buccal Cells. Proc. Natl. Acad. Sci. U S A.117 (38), 23329–23335. 10.1073/pnas.1820843116
38
MiyanoM.SayamanR. W.ShalabiS. F.SenapatiP.LopezJ. C.AngarolaB. L.et al (2021). Breast-Specific Molecular Clocks Comprised of ELF5 Expression and Promoter Methylation Identify Individuals Susceptible to Cancer Initiation. Cancer Prev. Res. (Phila)14 (8), 779–794. 10.1158/1940-6207.CAPR-20-0635
39
MoskalevA. A.ShaposhnikovM. V.PlyusninaE. N.ZhavoronkovA.BudovskyA.YanaiH.et al (2013). The Role of DNA Damage and Repair in Aging through the Prism of Koch-like Criteria. Ageing Res. Rev.12 (2), 661–684. 10.1016/j.arr.2012.02.001
40
OltraS. S.Peña-ChiletM.FlowerK.MartinezM. T.AlonsoE.BurguesO.et al (2019). Acceleration in the DNA Methylation Age in Breast Cancer Tumours from Very Young Women. Sci. Rep.9 (1), 14991. 10.1038/s41598-019-51457-6
41
PernaL.ZhangY.MonsU.HolleczekB.SaumK. U.BrennerH. (2016). Epigenetic Age Acceleration Predicts Cancer, Cardiovascular, and All-Cause Mortality in a German Case Cohort. Clin. Epigenetics8, 64. 10.1186/s13148-016-0228-z
42
PetronisA. (2010). Epigenetics as a Unifying Principle in the Aetiology of Complex Traits and Diseases. Nature465 (7299), 721–727. 10.1038/nature09230
43
PikeM. C.KrailoM. D.HendersonB. E.CasagrandeJ. T., (1983). 'Hormonal' Risk Factors, 'breast Tissue Age' and the Age-Incidence of Breast Cancer. Nature303 (5920), 767–770. 10.1038/303767a0
44
PikeM. C.SpicerD. V.DahmoushL.PressM. F. (1993). Estrogens, Progestogens, normal Breast Cell Proliferation, and Breast Cancer Risk. Epidemiol. Rev.15 (1), 17–35. 10.1093/oxfordjournals.epirev.a036102
45
RickabaughT. M.BaxterR. M.SehlM.SinsheimerJ. S.HultinP. M.HultinL. E.et al (2015). Acceleration of Age-Associated Methylation Patterns in HIV-1-Infected Adults. PLoS One10 (3), e0119201. 10.1371/journal.pone.0119201
46
SehlM. E.HenryJ. E.StornioloA. M.GanzP. A.HorvathS. (2017). DNA Methylation Age Is Elevated in Breast Tissue of Healthy Women. Breast Cancer Res. Treat.164 (1), 209–219. 10.1007/s10549-017-4218-4
47
SehlM. E.HenryJ. E.StornioloA. M.HorvathS.GanzP. A. (2021). The Effects of Lifetime Estrogen Exposure on Breast Epigenetic Age. Cancer Epidemiol. Biomarkers Prev.30, 1241–1249. 10.1158/1055-9965.EPI-20-1297
48
ShirebyG. L.DaviesJ. P.FrancisP. T.BurrageJ.WalkerE. M.NeilsonG. W. A.et al (2020). Recalibrating the Epigenetic Clock: Implications for Assessing Biological Age in the Human Cortex. Brain143 (12), 3763–3775. 10.1093/brain/awaa334
49
SnirS.FarrellC.PellegriniM. (2019). Human Epigenetic Ageing Is Logarithmic with Time across the Entire Lifespan. Epigenetics14 (9), 912–926. 10.1080/15592294.2019.1623634
50
StubbsT. M.BonderM. J.StarkA. K.KruegerF.TeamB. I. A. C.von MeyennF.et al (2017). Multi-tissue DNA Methylation Age Predictor in Mouse. Genome Biol.18 (1), 68. 10.1186/s13059-017-1203-5
51
TeschendorffA. E.GaoY.JonesA.RuebnerM.BeckmannM. W.WachterD. L.et al (2016). DNA Methylation Outliers in normal Breast Tissue Identify Field Defects that Are Enriched in Cancer. Nat. Commun.7, 10478. 10.1038/ncomms10478
52
TeschendorffA. E.MenonU.Gentry-MaharajA.RamusS. J.WeisenbergerD. J.ShenH.et al (2010). Age-dependent DNA Methylation of Genes that Are Suppressed in Stem Cells Is a Hallmark of Cancer. Genome Res.20 (4), 440–446. 10.1101/gr.103606.109
53
TeschendorffA. E.WidschwendterM. (2012). Differential Variability Improves the Identification of Cancer Risk Markers in DNA Methylation Studies Profiling Precursor Cancer Lesions. Bioinformatics28 (11), 1487–1494. 10.1093/bioinformatics/bts170
54
VaissièreT.HungR. J.ZaridzeD.MoukeriaA.CueninC.FasoloV.et al (2009). Quantitative Analysis of DNA Methylation Profiles in Lung Cancer Identifies Aberrant DNA Methylation of Specific Genes and its Association with Gender and Cancer Risk Factors. Cancer Res.69 (1), 243–252. 10.1158/0008-5472.CAN-08-2489
55
VoisinS.HarveyN. R.HauptL. M.GriffithsL. R.AshtonK. J.CoffeyV. G.et al (2020). An Epigenetic Clock for Human Skeletal Muscle. J. Cachexia Sarcopenia Muscle11 (4), 887–898. 10.1002/jcsm.12556
56
XieW.KagiampakisI.PanL.ZhangY. W.MurphyL.TaoY.et al (2018). DNA Methylation Patterns Separate Senescence from Transformation Potential and Indicate Cancer Risk. Cancer Cell33 (2), 309–e5. 10.1016/j.ccell.2018.01.008
57
YangZ.WongA.KuhD.PaulD. S.RakyanV. K.LeslieR. D.et al (2016). Correlation of an Epigenetic Mitotic Clock with Cancer Risk. Genome Biol.17 (1), 205. 10.1186/s13059-016-1064-3
58
YounA.WangS. (2018). The MiAge Calculator: a DNA Methylation-Based Mitotic Age Calculator of Human Tissue Types. Epigenetics13 (2), 192–206. 10.1080/15592294.2017.1389361
59
YuM.HazeltonW. D.LuebeckG. E.GradyW. M. (2020). Epigenetic Aging: More Than Just a Clock when it Comes to Cancer. Cancer Res.80 (3), 367–374. 10.1158/0008-5472.CAN19-0924
60
ZhengC.LiL.XuR. (2019). Association of Epigenetic Clock with Consensus Molecular Subtypes and Overall Survival of Colorectal Cancer. Cancer Epidemiol. Biomarkers Prev.28 (10), 1720–1724. 10.1158/1055-9965.EPI-19-0208
61
ZhengY.JoyceB. T.ColicinoE.LiuL.ZhangW.DaiQ.et al (2016). Blood Epigenetic Age May Predict Cancer Incidence and Mortality. EBioMedicine5, 68–73. 10.1016/j.ebiom.2016.02.008
Summary
Keywords
aging, epigenetic clocks, DNA methylation, carcinogenesis, cancer risk
Citation
Chen L, Ganz PA and Sehl ME (2022) DNA Methylation, Aging, and Cancer Risk: A Mini-Review. Front. Bioinform. 2:847629. doi: 10.3389/fbinf.2022.847629
Received
03 January 2022
Accepted
21 March 2022
Published
02 June 2022
Volume
2 - 2022
Edited by
Christine Nardini, National Research Council (CNR), Italy
Reviewed by
Claudia Sala, University of Bologna, Italy
Updates
Copyright
© 2022 Chen, Ganz and Sehl.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mary E. Sehl, msehl@mednet.ucla.edu
This article was submitted to Genomic Analysis, a section of the journal Frontiers in Bioinformatics
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.